The New York Times, February 24, 2021 (with Noah Weiland and Sharon LaFraniere)

Link

The coronavirus vaccine made by Johnson & Johnson provides strong protection against severe disease and death from Covid-19, and may reduce the spread of the virus by vaccinated people, according to new analyses released Wednesday by the company and the Food and Drug Administration.

The reports provided confirmation of the initial results announced by Johnson & Johnson late last month, indicating that the United States is likely to soon have access to a third coronavirus vaccine developed in under a year. The F.D.A. could authorize the vaccine as early as Saturday, depending on a vote by its vaccine advisory panel on Friday, and distribution could begin within days.

Continue reading “Johnson & Johnson’s Vaccine Works Well and May Curb Virus Spread” →

The New York Times, February 23, 2021

Link

A variant first discovered in California in December is more contagious than earlier forms of the coronavirus, two new studies have shown, fueling concerns that emerging mutants like this one could hamper the sharp decline in cases over all in the state and perhaps elsewhere.

In one of the new studies, researchers found that the variant has spread rapidly in a San Francisco neighborhood in the past couple of months. The other report confirmed that the variant has surged across the state, and revealed that it produces twice as many viral particles inside a person’s body as other variants do. That study also hinted that the variant may be better than others at evading the immune system — and vaccines.

“I wish I had better news to give you — that this variant is not significant at all,” said Dr. Charles Chiu, a virologist at the University of California, San Francisco. “But unfortunately, we just follow the science.”

Continue reading “Studies Examine Variant Surging in California, and the News Isn’t Good” →

The New York Times, February 22, 2021 (with Noah Weiland and Katie Thomas)

Link

The Food and Drug Administration said on Monday that vaccine developers would not need to conduct lengthy randomized controlled trials for vaccines that have been adapted to protect against concerning coronavirus variants.

The recommendations, which call for small trials more like those required for annual flu vaccines, would greatly accelerate the review process at a time when scientists are increasingly anxious about how the variants might slow or reverse progress made against the virus.

Continue reading “Vaccines Adapted for Variants Will Not Need Lengthy Testing, F.D.A. Says” →

The New York Times, February 17, 2021 (with Noah Weiland)

Link

As lawmakers push for billions of dollars to fund the nation’s efforts to track coronavirus variants, the Biden administration announced on Wednesday a new effort to ramp up this work, pledging nearly $200 million to better identify the emerging threats.

Continue reading “C.D.C. Announces $200 Million ‘Down Payment’ to Track Virus Variants” →